Benign fabrication of microfluidic hydrogel for improved artificial vasculature in bone implants

我们将创造一种良性的技术来合成微流体水凝胶，在骨植入物中产生人工血管。这是一个关键的步骤，使组织工程的重要器官，如骨，心脏和肾脏的终末期器官衰竭患者的使用。更厚的支架将是可能的，因为脉管系统将为细胞生长成3D支架提供营养和氧气。它将提高澳大利亚制造全球组织工程生物材料产品的能力。我们还将开发用于快速分析广泛功能分子阵列的原位成像分析协议，对BioMEMS设计具有重要意义，以开发诊断致命疾病的方法。

We will create a benign technology for synthesising microfluidic hydrogels to generate artificial vascultures in bone implants. It is a critical step to enable the use of tissue-engineered vital organs, such as bone, heart and kidney in patients with end-stage organ failure. Thicker scaffolds will be possible, as the vasculature will provide nutrients and oxygen for cells to grow into 3D scaffolds. It will promote capacity of Australia for manufacturing global biomaterial products for tissue engineering. We will also develop in-situ imaging analytical protocols for the rapid analysis of broad arrays of functional molecules, with significant bearing on BioMEMS design to develop methods for diagnosis of fatal diseases.